Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Immatics launches US$250m Nasdaq-IPO

T cell therapy specialist Immatics N.V.  achieved an initial market capitalisation of US$253m through a mixture of Nasdaq listing and...

Calliditas Therapeutics raise US$90m in Nasdaq IPO

For its listing on The Nasdaq Global Select Market through a capital increase, NASDAQ Stockholm-listed Calliditas Therapeutics AB set the price of...

Roche gets FDA okay for COVID-19 antibody test

The US Food and Drug Administration has granted Emergence use approval (EUA) to Roche Diagostics GmbH’s new Elecsys® Anti-SARS-CoV-2 antibody...

COVID-19: Novartis starts study on hyped malaria drug

Cardiologists have red-flagged combination therapies of cloroquine phosphate (Resochin, Bayer AG, Germany) or hydroxychloroquine (Novartis AG, Basel)...

COVID-19: Solnatide approved for compassionate use

The more COVID-19 patients reach advanced disease stages according to the eight-level WHO disease scale, the more important it becomes to treat...

Hyloris Pharmaceuticals prepared to go public

Reformulation specialist Hyloris Pharmaceuticals SA  wants to go public on the regulated market of Euronext Brussels. The company reformulates...

GE renamed Cytiva upon take-over by Danaher

The acquisition of GE Healthcare Life Sciences by Danaher Corporation creates a giant in contract manufacturing and development. While GE Healthcare...